180 related articles for article (PubMed ID: 28593739)
1. Systematic review and meta-analysis to determine the impact of iron depletion in dysmetabolic iron overload syndrome and non-alcoholic fatty liver disease.
Murali AR; Gupta A; Brown K
Hepatol Res; 2018 Feb; 48(3):E30-E41. PubMed ID: 28593739
[TBL] [Abstract][Full Text] [Related]
2. Dysmetabolic Hyperferritinemia and Dysmetabolic Iron Overload Syndrome (DIOS): Two Related Conditions or Different Entities?
Rametta R; Fracanzani AL; Fargion S; Dongiovanni P
Curr Pharm Des; 2020; 26(10):1025-1035. PubMed ID: 32003680
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia.
Valenti L; Fracanzani AL; Dongiovanni P; Rovida S; Rametta R; Fatta E; Pulixi EA; Maggioni M; Fargion S
World J Gastroenterol; 2014 Mar; 20(11):3002-10. PubMed ID: 24659891
[TBL] [Abstract][Full Text] [Related]
4. Hyperferritinemia in Nonalcoholic Fatty Liver Disease: Iron Accumulation or Inflammation?
Moris W; Verhaegh P; Jonkers D; Deursen CV; Koek G
Semin Liver Dis; 2019 Nov; 39(4):476-482. PubMed ID: 31330553
[TBL] [Abstract][Full Text] [Related]
5. Metabolic and hepatic effects of bloodletting in dysmetabolic iron overload syndrome: A randomized controlled study in 274 patients.
Lainé F; Ruivard M; Loustaud-Ratti V; Bonnet F; Calès P; Bardou-Jacquet E; Sacher-Huvelin S; Causse X; Beusnel C; Renault A; Bellissant E; Deugnier Y;
Hepatology; 2017 Feb; 65(2):465-474. PubMed ID: 27685251
[TBL] [Abstract][Full Text] [Related]
6. Dysmetabolic Iron Overload in Metabolic Syndrome.
Sachinidis A; Doumas M; Imprialos K; Stavropoulos K; Katsimardou A; Athyros VG
Curr Pharm Des; 2020; 26(10):1019-1024. PubMed ID: 32000639
[TBL] [Abstract][Full Text] [Related]
7. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study.
Valenti L; Fracanzani AL; Dongiovanni P; Bugianesi E; Marchesini G; Manzini P; Vanni E; Fargion S
Am J Gastroenterol; 2007 Jun; 102(6):1251-8. PubMed ID: 17391316
[TBL] [Abstract][Full Text] [Related]
8. Metabolomic profiling identifies potential pathways involved in the interaction of iron homeostasis with glucose metabolism.
Stechemesser L; Eder SK; Wagner A; Patsch W; Feldman A; Strasser M; Auer S; Niederseer D; Huber-Schönauer U; Paulweber B; Zandanell S; Ruhaltinger S; Weghuber D; Haschke-Becher E; Grabmer C; Rohde E; Datz C; Felder TK; Aigner E
Mol Metab; 2017 Jan; 6(1):38-47. PubMed ID: 28123936
[TBL] [Abstract][Full Text] [Related]
9. Outcome of phlebotomy for treating nonalcoholic fatty liver disease: A systematic review and meta-analysis.
Jaruvongvanich V; Riangwiwat T; Sanguankeo A; Upala S
Saudi J Gastroenterol; 2016 Nov; 22(6):407-414. PubMed ID: 27976635
[TBL] [Abstract][Full Text] [Related]
10. Hepcidin levels correlate to liver iron content, but not steatohepatitis, in non-alcoholic fatty liver disease.
Marmur J; Beshara S; Eggertsen G; Onelöv L; Albiin N; Danielsson O; Hultcrantz R; Stål P
BMC Gastroenterol; 2018 Jun; 18(1):78. PubMed ID: 29871592
[TBL] [Abstract][Full Text] [Related]
11. Effects of Synbiotics, Probiotics, and Prebiotics on Liver Enzymes of Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis.
Kanchanasurakit S; Kositamongkol C; Lanoi K; Nunta M; Saetuan T; Chaiyakunapruk N; Saokaew S; Phisalprapa P
Front Nutr; 2022; 9():880014. PubMed ID: 35669067
[TBL] [Abstract][Full Text] [Related]
12. Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling--a propensity score-adjusted observational study.
Valenti L; Moscatiello S; Vanni E; Fracanzani AL; Bugianesi E; Fargion S; Marchesini G
QJM; 2011 Feb; 104(2):141-9. PubMed ID: 20851820
[TBL] [Abstract][Full Text] [Related]
13. Effects of Phlebotomy on Liver Enzymes and Histology of Patients with Nonalcoholic Fatty Liver Disease.
Khodadoostan M; Zamanidoost M; Shavakhi A; Sanei H; Shahbazi M; Ahmadian M
Adv Biomed Res; 2017; 6():12. PubMed ID: 28299304
[TBL] [Abstract][Full Text] [Related]
14. The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial.
Adams LA; Crawford DH; Stuart K; House MJ; St Pierre TG; Webb M; Ching HL; Kava J; Bynevelt M; MacQuillan GC; Garas G; Ayonrinde OT; Mori TA; Croft KD; Niu X; Jeffrey GP; Olynyk JK
Hepatology; 2015 May; 61(5):1555-64. PubMed ID: 25524401
[TBL] [Abstract][Full Text] [Related]
15. Dysmetabolic iron overload syndrome.
Deugnier Y; Bardou-Jacquet É; Lainé F
Bull Acad Natl Med; 2016 Feb; 200(2):327-333. PubMed ID: 29898328
[TBL] [Abstract][Full Text] [Related]
16. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Li Y; Liu L; Wang B; Wang J; Chen D
Biomed Rep; 2013 Jan; 1(1):57-64. PubMed ID: 24648894
[TBL] [Abstract][Full Text] [Related]
17. Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis.
Dajani AI; Popovic B
World J Clin Cases; 2020 Nov; 8(21):5235-5249. PubMed ID: 33269259
[TBL] [Abstract][Full Text] [Related]
18. Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Fernández T; Viñuela M; Vidal C; Barrera F
PLoS One; 2022; 17(2):e0263931. PubMed ID: 35176096
[TBL] [Abstract][Full Text] [Related]
19. Non-invasive methods for iron overload evaluation in dysmetabolic patients.
Branisso PPF; de Oliveira CPMS; Filho HML; Lima FR; Santos AS; Mancini MC; de Melo ME; Carrilho FJ; Rocha MS; Clark P; Branisso HJP; Cercato C
Ann Hepatol; 2022; 27(4):100707. PubMed ID: 35477031
[TBL] [Abstract][Full Text] [Related]
20. Iron overload and non-alcoholic fatty liver disease.
Datz C; Müller E; Aigner E
Minerva Endocrinol; 2017 Jun; 42(2):173-183. PubMed ID: 27834478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
